|
1
|
Wolff JM and Mason M: Drivers for change
in the management of prostate cancer - guidelines and new treatment
techniques. BJU Int. 109 Suppl 6:33–41. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sfanos KS, Yegnasubramanian S, Nelson WG
and De Marzo AM: The inflammatory microenvironment and microbiome
in prostate cancer development. Nat Rev Urol. 15:11–24. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kenfield SA, Tat D and Chan JM: The
potential benefits of diet and physical activity among active
surveillance patients with low-burden prostate cancer. In: Active
Surveillance for Localized Prostate CancerCurrent clinical urology.
Klotz L: Humana Press; Totowa, NJ: 2012
|
|
4
|
Baade PD, Youlden DR, Cramb SM, Dunn J and
Gardiner RA: Epidemiology of prostate cancer in the Asia-Pacific
region. Prostate Int. 1:47–58. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Esfahani M, Ataei N and Panjehpour M:
Biomarkers for evaluation of prostate cancer prognosis. Asian Pac J
Cancer Prev. 16:2601–2611. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Marantz PR, Hall CB and Derby CA: Radical
prostatectomy versus watchful waiting. N Engl J Med. 353:1298–1300.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Carthew RW: Gene regulation by microRNAs.
Curr Opin Genet Dev. 16:203–208. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Iorio MV and Croce CM: MicroRNA
dysregulation in cancer: Diagnostics, monitoring and therapeutics.
A comprehensive review. EMBO Mol Med. 4:143–159. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ferretti S, Patriarca S, Carbone A and
Zanetti R: TNM classification of malignant tumours, VII edition
2009. Changes and practical effects on cancer epidemiology.
Epidemiol Prev. 34:125–128. 2010.(In Italian). PubMed/NCBI
|
|
10
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
White A, Joseph D, Rim SH, Johnson CJ,
Coleman MP and Allemani C: Colon cancer survival in the United
States by race and stage (2001–2009): Findings from the CONCORD-2
study. Cancer. 123 Suppl 24:5014–5036. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Thorstenson A, Garmo H, Adolfsson J and
Bratt O: Cancer specific mortality in men diagnosed with prostate
cancer before age 50 years: A nationwide population based study. J
Urol. 197:61–66. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Pokharel SS, Patel NU, Garg K, La Rosa FG,
Arangua P, Jones C and Crawford ED: Multi-parametric MRI findings
of transitional zone prostate cancers: Correlation with
3-dimensional transperineal mapping biopsy. Abdom Imaging.
40:143–150. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ha M and Kim VN: Regulation of microRNA
biogenesis. Nat Rev Mol Cell Biol. 15:509–524. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Carthew RW: Gene regulation by microRNAs.
Curr Opin Genet Dev. 16:203–208. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Nishikawa R, Goto Y, Kojima S, Enokida H,
Chiyomaru T, Kinoshita T, Sakamoto S, Fuse M, Nakagawa M, Naya Y,
et al: Tumor-suppressive microRNA-29s inhibit cancer cell migration
and invasion via targeting LAMC1 in prostate cancer. Int J Oncol.
45:401–410. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Moltzahn F, Olshen AB, Baehner L, Peek A,
Fong L, Stöppler H, Simko J, Hilton JF, Carroll P and Blelloch R:
Microfluidic-based multiplex qRT-PCR identifies diagnostic and
prognostic microRNA signatures in the sera of prostate cancer
patients. Cancer Res. 71:550–560. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ling XH, Han ZD, Xia D, He HC, Jiang FN,
Lin ZY, Fu X, Deng YH, Dai QS, Cai C, et al: MicroRNA-30c serves as
an independent biochemical recurrence predictor and potential tumor
suppressor for prostate cancer. Mol Biol Rep. 41:2779–2788. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Huang Z, Zhang L, Yi X and Yu X:
Diagnostic and prognostic values of tissue hsa-miR-30c and
hsa-miR-203 in prostate carcinoma. Tumour Biol. 37:4359–4365. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhang J, Wang X, Wang Y, Peng R, Lin Z,
Wang Y, Hu B, Wang J and Shi G: Low expression of microRNA-30c
promotes prostate cancer cells invasion involved in downregulation
of KRAS protein. Oncol Lett. 14:363–368. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Steele R, Mott JL and Ray RB: MBP-1
upregulates miR-29b that represses Mcl-1, collagens, and
matrix-metalloproteinase-2 in prostate cancer cells. Genes Cancer.
1:381–387. 2010. View Article : Google Scholar : PubMed/NCBI
|
